Latest news

Thumbnail

Study data back efficacy of AZ novel antibiotic

A late-stage study has confirmed the efficacy of AstraZeneca's new combination antibiotic Zavicefta in patients with hospital acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).

22nd July 2016

Thumbnail

US delay to Merck’s C.difficile antitoxin

Merck & Co's investigational clostridium difficile treatment has been hit with a setback in the US after regulators extended the review time for the drug by three months.

22nd July 2016

Thumbnail

Industry roundup – 21 July

Biobank banks genes of long-lived Sardinians; stem cell therapies face commercial challenges; VBI moves forward with Zika Vaccine

21st July 2016

Thumbnail

Lilly’s Alimta wins NICE support

NHS use of Eli Lilly's Alimta to treat patients with lung cancer has been endorsed in final draft guidance from the National Institute for Health and Care Excellence.

21st July 2016

Thumbnail

EU orphan status for Cell Medica drug

London, UK-based Cell Medica has received European Commission orphan drug designations for its lead cancer immunotherapy CMD-003 (baltaleucel-T).

21st July 2016

Thumbnail

EU nod for AZ’ diabetes therapy Qtern

The European Commission has green-lighted Qtern (saxagliptin/dapagliflozin) for the treatment of type II diabetes in all 28 EU member countries plus Iceland, Liechtenstein and Norway.

21st July 2016

Thumbnail

EU clears Gilead’s pan-genotypic hepatitis C therapy

Gilead's Sovaldi-based combination therapy for hepatitis C has been cleared for use by European regulators to treat all six types of the virus, potentially eliminating the need for genotype testing.

20th July 2016

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download